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Background: This study investigated whether polymorphisms of the ankyrin repeat and kinase domain containing
1 gene (ANKK1), which is adjacent to the dopamine D2 receptor gene (DRD2), and the dopamine transporter
(SLC6A3) and cytochrome P450 2A6 (CYP2A6) genes influence smoking cessation and nicotine dependence in a
Japanese population. In 96 current and former smokers, genotyping frequencies for the ANKK1/DRD2 TaqIA, SLC6A3
VNTR, and CYP2A6 polymorphisms were subjected to chi-square analysis, and regression analyses were used to
determine the association of the genotypes of current smokers with a Heavy Smoking Index, in addition to evaluating
the effect of the subjects’ smoking history on the association.
Results: Genotyping results suggested that nicotine dependence among current smokers homozygous for the SLC6A3
10r allele was lower than that of smokers carrying the minor alleles, and that the CYP2A6 polymorphism might mediate
this association. Furthermore, the age at which current smokers began smoking might moderate the association
between their genetic polymorphisms and nicotine dependence.
Conclusions: This study provides preliminary findings on the influence of genetic variants on the smoking phenotypes
in a Japanese population.
Keywords: ANKK1/DRD2 TaqIA polymorphism, CYP2A6*4 polymorphism, Nicotine dependence SLC6A3 VNTR
polymorphism, Smoking cessationBackground
Nicotine activates the mesolimbic dopaminergic system
and mediates positive reinforcing reward effects, primarily
by releasing dopamine in the nucleus accumbens [1].
Although smoking behaviour is affected by a combination
of genetic and environmental factors, genetic factors are
known to play a key role in some aspects of smoking
behaviour [2]. The association of specific genetic variants
with the molecular mechanisms underlying the behavioural
phenotypes of nicotine addiction has been investigated
extensively, with a focus on dopaminergic transmis-
sions. The TaqIA polymorphism (rs1800497) of the
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unless otherwise stated.(ANKK1) [3]—adjacent to the dopamine D2 receptor
gene (DRD2)—is known to be associated with smoking
behaviour. Several surveys [4,5], predominantly with
Caucasian subjects, have suggested that the A1 allele
of this polymorphism increases the risk of smoking,
whereas studies with Japanese subjects showed an associ-
ation between the A2/A2 genotype and smoking risk [6,7].
We previously reviewed the effect of ANKK1/DRD2 poly-
morphisms on smoking behaviour by considering the influ-
ence of ethnicity [8]. Our meta-analysis revealed a significant
effect of ANKK1/DRD2 polymorphisms on smoking cessa-
tion, which suggested that Caucasians carrying the A1 allele
of the Taq1A polymorphism have a lower probability of
smoking cessation than Asians do. It has been reported that
the frequency of the A1 allele was higher in Americans
(53–75%) than in Asians (11–58%) [9]. These significantl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ohmoto et al. BMC Genetics  (2014) 15:151 Page 2 of 9ethnic differences in allele and genotype frequencies may be
responsible for the inconsistent findings in previous studies
on the role of the Taq1A ANKK1/DRD2 polymorphism in
the smoking behaviour of Caucasians and Asians.
The dopamine transporter (SLC6A3) terminates synaptic
transmission by the rapid and specific reuptake of dopa-
mine in the synaptic clefts. Lerman et al. [10] investigated
the association of smoking risk with the variable number
of tandem repeat (VNTR) polymorphisms (rs28363170) in
SLC6A3, in combination with the TaqIA polymorphism,
and found polymorphism–polymorphism interaction, in
which individuals with the SCL6A3 VNTR genotype that
includes the 9-repeat (9r) allele were significantly less likely
to be smokers, particularly if they also carried the TaqIA
A2 allele. Sabol et al. [11] also demonstrated the significant
effect of SLC6A3 9r genotypes on smoking cessation. How-
ever, other reports [12-14] did not replicate the initial posi-
tive results [10,11]. In studies of association between
variant alleles of ANKK1/DRD2 and SLC6A3 and smoking,
it has been suggested that the presence of the ANKK1/
DRD2 TaqIA A1 allele along with the SLC6A3 9r allele
increases cigarette craving that is induced by a stressor
[15,16] and smoking reward and reinforcement by indu-
cing a negative mood [17]. Furthermore, several reports
[10,14,18] have suggested that compared to non-carriers,
carriers of SLC6A3 9r allele have a lower risk of starting to
smoke early.
The genetic effect of the pharmacokinetics of nicotine on
the association between alterations in synaptic dopamine
levels and smoking phenotypes has not been well docu-
mented to data. Nicotine in the blood is metabolised into
cotinine mainly by cytochrome P450 (CYP) 2A6. One of
the functional polymorphisms of CYP2A6, the *4 allele, is a
particularly important polymorphic variant, with a gene
deletion that is common in Asian populations [19]. It
accounts for the majority of individuals with poor metabol-
ism. Minematsu et al. [20] have reported that carriers of the
*4 allele among Japanese smokers are more likely to be light
rather than heavy smokers. Kubota et al. [21] also demon-
strated that CYP2A6 genotypes including the *4 allele are
associated with nicotine dependence and withdrawal symp-
toms upon smoking cessation. These reports have sug-
gested that smoking-related phenotypes may be influenced
by altering the nicotine concentration in the brain as a se-
quel to reduced nicotine metabolism. We hypothesized that
the association between the ANKK1/DRD2 and SLC6A3
polymorphisms and smoking-related phenotypes might be
influenced by variants in CYP2A6.
In light of the lack of research in polymorphism–poly-
morphism interactions in the Japanese population, we here
investigated whether the combined polymorphic variants of
SLC6A3 and ANKK1/DRD2, in the context of CYP2A6*4
genotypes, are associated with smoking-related phenotypes
in a Japanese population, focussing on smoking cessationand nicotine dependence. Previous genetic association stud-
ies of these polymorphisms with smoking cessation and
nicotine dependence are described briefly in Table 1. The
present study also examined the effect of smoking history
(age at which the participant began smoking and duration
of smoking) on the association between SLC6A3,
ANKK1/DRD2, and CYP2A6 polymorphisms and nicotine
dependence.
Results
The allele and genotype frequencies for the SLC6A3,
ANKK1/DRD2, and CYP2A6 polymorphisms in relation
to smoking status for the 75 current and 21 former
smokers are shown in Table 2. The distributions of the
SLC6A3 VNTR and ANKK1/DRD2 TaqIA genotypes in
current smokers, former smokers, and all participants
did not deviate from Hardy-Weinberg equilibrium (HWE)
to any appreciable extent, as determined by chi-squared
tests. The allele frequencies of the SLC6A3 VNTR,
ANKK1/DRD2 TaqIA, and CYP2A6*4 polymorphisms in
all participants were similar to those from previous studies
in Japanese populations [6,7,33,34]. Although the distribu-
tion of CYP2A6*4 genotypes in former smokers and all
participants were different, the allele frequency of
CYP2A6*4 in all participants were similar to those
from a previous study [20].
The sex ratio and mean and standard deviation for age
and smoking history of the participants, categorized by
smoking status for each genotype of the SLC6A3, ANKK1/
DRD2, and CYP2A6 polymorphisms, are shown in Table 3.
There was no significant difference in age and smoking
histories of participants among genotypes.
The gender ratio of the study population was skewed
(see Table 2). Therefore, we performed analyses for the
cohort as a whole (n = 96) as well as for the male sub-
group only (n = 88). As shown in Table 4, subgrouping
did not have an effect on detecting associations between
the overall genotype frequencies and smoking status.
To assess whether the genotypes were associated with
the Heavy Smoking Index (HSI) [35], as a measure of the
degree of nicotine dependence, the HSI scores for current
smokers were compared for each genotype, both in the
whole cohort and in males only (Table 5). There was a sig-
nificant association between the SLC6A3 VNTR polymor-
phisms and the HSI score, whereas no associations were
found between the ANKK1/DRD2 TaqIA and CYP2A6 ge-
notypes and the HSI score. The number of smokers with
the CYP2A6*1/*1 genotype showing an HSI high-score was
two-fold higher than that of smokers carrying the *4 allele.
Moreover, we evaluated the effect of the ANKK1/DRD2
and CYP2A6 genotypes on the association between the
SLC6A3 VNTR polymorphism and the HSI score (Table 6).
Regression analyses showed that the HSI score correlated
better with the SLC6A3 VNTR and CYP2A6 genotypes
Table 1 Association between smoking behaviour and nicotine dependence and ANKK1/DRD2 TaqIA, SLC6A3 VNTR, and
CYP2A6 polymorphisms
Study Ethnicity Samples Association Reference
ANKK1/DRD2 TaqIA polymorphism
Noble et al. (1994) Caucasians 57 current smokers, 115 former
smokers, and 182 non-smokers
Smoking subjects showed a significantly higher
prevalence of the A1 allele compared to controls. Both
past and current smokers demonstrated a significantly
higher prevalence of the A1 allele than non-smokers did.
[4]
Comings et al. (1996) Caucasians 312 smokers There was a significant, inverse relationship between
the prevalence of the A1 allele and the age of onset
of smoking, and the maximum duration of time that
smokers had been able to quit smoking on their own.
[5]
Batra et al. (2000) Caucasians 110 heavy smokers and 60 light
smokers
No significant findings [22]
Bierut et al. (2000) Caucasians 388 habitual smokers and 566
non-habitual smokers
No significant findings [23]
Yoshida et al. (2001) Japanese 77 current smokers, 57 former
smokers, and 198 never smokers
Smoking appeared to be associated with the A2/A2
genotype.
[6]
Hamajima et al, (2002) Japanese 226 current smokers, 133 former
smokers, and 434 never smokers
Males with the A2/A2 genotype had a higher risk of
being current smokers.
[7]
Johnstone et al. (2004) Caucasians 752 smokers At 1 week, the nicotine patch was more effective for
smokers with the A1/A2 or A1/A1 genotypes than for
those with the A2/A2 genotype; this was not the case
at the 12-week flow up.
[24]
Morton et al. (2006) Caucasians 1068 smokers, 213 non-smoking,
and 1093 former smokers
Current smokers were more likely than former
smokers to possess the A1 allele.
[25]
Connor et al. (2007) Caucasians 84 smokers Compared to carriers of the A2/A2 genotype, carriers
of the A1/A1 or A1/A2 genotypes were characterised
by higher levels of cigarette consumption.
[26]
SLC6A3 VNTR polymorphism
Lerman et al. (1999) Caucasians (85%)
African
Americans (15%)
289 smokers and 233 non-
smokers
Individuals with the 9r allele were significantly less
likely to be smokers, particularly if they also carried
the A2/A2 genotype. Smokers carrying the 9r allele
genotype were also significantly less likely to have
started smoking before 16 years of age and had prior
smoking histories, indicating a longer period of prior
smoking cessation.
[10]
Sabol et al. (1999) Caucasians 164 current smokers and 111
former smokers
The 9r allele was associated with smoking cessation. [11]
Jorm et al. (2000) Caucasians 211 former smokers, 198 current
smokers, and 452 non-smokers
No associations were found with either smoking
initiation or smoking cessation.
[12]
Vandenbergh et al. (2002) Caucasians 153 former smokers, 98 current
smokers, 214 never smokers, and
114 non-smokers
Never smokers showed a higher prevalence of the 10r
allele compared to current smokers. The frequency of
the 10r allele in never-smokers (no cigarettes ever)
was more than that in other smokers.
[13]
Perkins et al. (2008) Caucasians 72 smoker The increase in smoking amount owing to negative
mood was associated with the A2/A2 allele and the 9r
allele.
[17]
Laucht et al. (2008) Caucasians 220 ever smokers (adolescents) The A1 allele scored higher on nicotine dependence
than their allelic counterparts. The intention to quit
smoking was significantly lower in adolescents for the
10r/10r genotype.
[27]
Sieminska et al. (2009) Caucasians 150 ever smokers and 158 never
smokers
The abstinence periods during quitting attempts of
carriers of the A1 allele were longer than those of
non-carriers. The odds ratio for heavy smoking was
higher in carriers of the A1 or 9r alleles compared to
that in non-carriers. Compared to non-carriers, carriers
of the 9r allele had a lower risk to start smoking
before the age of 20 years.
[14]
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Table 1 Association between smoking behaviour and nicotine dependence and ANKK1/DRD2 TaqIA, SLC6A3 VNTR, and
CYP2A6 polymorphisms (Continued)
CYP2A6 polymorphism (*4 allele)
Tan et al. (2001) Chinese 174 smokers and 152 non-
smokers
The distribution of the CYP2A6 genotype frequencies
was not significantly different.
[28]
Loriot et al. (2001) Caucasians 185 heavy smokers and 203 light
smokers
No significant relationship between genetically
impaired nicotine metabolism and cigarette
consumption related and the presence of defective
CYP2A6 alleles (*2 and *4 alleles).
[29]
Ando et al. ( 2003) Japanese 57 current smokers, 44 former
smokers, and 139 never smokers
The proportion of never smokers among
heterozygous carriers of the *4 allele was similar
among subjects with the *1/*1 genotype. CYP2A6
genotypes did not correlate either with the number
of cigarettes smoked per day or with the age of
smoking commencement.
[30]
Minematsu et al. (2003) Japanese 92 current smokers, 111 former
smokers, and 123 non-smoker
The percentage of subjects with a CYP2A6del (*4)
allele was lower among heavy smokers than among
light smokers or non-smokers and was lower among
ex-smokers than among current smokers.
[20]
Fujieda et al. (2004) Japanese 1094 patient (cancer) subjects
and 611 healthy subjects
The amount of daily cigarette consumption in
subjects who harboured the CYP2A6*4 allele was
significantly less than that in subjects carrying the
*1/*1 genotype.
[31]
Kubota et al. (2006) Japanese 107 smokers CYP2A6 high-activity group (CYP2A6*1/*1, *1/*4, etc.)
smoked the first cigarette of the day earlier than the
low-activity group (CYP2A6*4/*4), indicating more
marked nicotine dependence. Nicotine withdrawal
symptoms were more serious during smoking
cessation in the CYP2A6 high-activity group.
[21]
Liu et al. (2011) Chinese 970 current smokers and 358
former smokers
Poor metabolizers reported smoking fewer cigarettes
per day, started smoking regularly at a later age, and
smoked for a shorter duration than did normal
metabolizers. However, poor metabolizers were less
likely to quit smoking than normal metabolizers were.
[32]
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(AIC value: 75.327). Regression analysis of the male sub-
group only also showed a high correlation between the
HSI score and the SLC6A3 VNTR and CYP2A6 geno-
types, although this did not reach statistical significance
(AIC value: 70.761; P = 0.018).
The proportion of HSI scores ≥4 for individuals with the
SLC6A3 10r/10r genotype was lower than that of individ-
uals with a single or no copy of the 10r allele, suggesting
that the CYP2A6 genotype might affect the relationship.
We performed regression analyses to determine the effect
of two variables in smoking histories on the association be-
tween nicotine dependence and genetic polymorphisms. As
shown in Table 7, the HSI score was significantly correlated
with the SLC6A3 VNTR and CYP2A6 genotypes when the
age at which the participant began smoking was included
as a variable in analysis of the whole cohort. Regression
analysis of the male subgroup only (AIC value: 74.250),
rather than that of the whole cohort (AIC value;
69.921), also showed a high correlation between the HSI
score and a 3-variable combination (SLC6A3 genotypes,
CYP2A6 genotypes, and age at which the participantbegan smoking), although this did not reach statistical
significance (P = 0.014).Discussion
This study examined whether functional polymorphisms
in SLC6A3, ANKK1/DRD2, and CYP2A6 affect smoking
cessation and nicotine dependence in a Japanese popula-
tion. We found that current smokers with the SLC6A3
10r/10r genotype were more likely to have low nicotine
dependence, based on HSI analysis, although the geno-
typic differences between current and former smokers
were not significant for any of the SLC6A3, ANKK1/
DRD2, and CYP2A6 polymorphisms tested. Previous
studies [36,37] suggested that the 9r allele enhanced the
expression of the SLC6A3 protein, resulting in reduced
postsynaptic dopamine activity. The 10r allele has been
implicated in reduced SLC6A3 protein expression; thus, it
might decrease the extent of nicotine dependence, by
increasing the total amount of dopamine that is released
into the synaptic cleft, thereby providing a greater reward
from the dopaminergic effects of nicotine.
Table 2 Allele frequency profiles for SLC6A3, ANKK1/DRD2,
and CYP2A6 polymorphism genotypes for current and
former smokers
Allele/Genotype Alla Current smoker Former smoker
Number % Number % Number %
SLC6A3
10r 172 89.6 136 90.7 36 85.7
9r 9 4.7 7 4.7 2 4.8
7r 8 4.2 6 4.0 2 4.8
6r 3 1.6 1 0.7 2 4.8
10r/10r 77 80.2 61 81.3 16 76.2
10r/9r 9 9.4 7 9.3 2 9.5
10r/7r 6 6.3 6 8.0 0 0.0
10r/6r 3 3.1 1 1.3 2 9.5
7r/7r 1 1.0 0 0.0 1 4.8
HWEb P-value 0.96 0.37 0.31
ANKK1/DRD2
A2 112 58.3 91 60.7 21 50.0
A1 80 41.7 59 39.3 21 50.0
A2/A2 33 34.4 27 36.0 6 28.6
A2/A1 46 47.9 37 49.3 9 42.9
A1/A1 17 17.7 11 14.7 6 28.6
HWEb P-value 0.89 0.77 0.51
CYP2A6
*1 164 85.4 126 84.0 38 90.5
*4 28 14.6 24 16.0 4 9.5
*1/*1 73 76.0 55 73.3 18 85.7
*1/*4 18 18.8 16 21.3 2 9.5
*4/*4 5 5.2 4 5.3 1 4.8
HWEb P-value 0.02 0.07 0.04
aNumber of alleles or genotypes for combined current and former smokers;
and bHardy-Weinberg equilibrium of genotype distributions of each
polymorphism was tested for current smokers, former smokers, and the
whole cohort.
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polymorphism and smoking cessation, initial studies [10,11]
and a meta-analysis [38] have suggested that individuals
carrying the 9r allele, rather than the more common 10r
allele, had a greater likelihood of smoking cessation. How-
ever, these results have not been replicated [12,13], and the
meta-analysis did not include Asian populations. Further
studies are therefore needed to clarify the effects of the 9r
and 10r alleles on smoking cessation.
As for the effect of the SLC6A3 VNTR polymorphism on
nicotine dependence, O’Gara et al. [39] reported a lack of
association between the SLC6A3 VNTR polymorphism and
the HSI score for smokers attempting to quit by using ei-
ther nicotine replacement therapy or bupropion. Nicotine
dependence has been estimated using the Fagerstrom Testfor Nicotine Dependence (FTND) [40]. De Leon et al. [41]
suggested that use of the FTND in epidemiological surveys
may lead to inaccurate conclusions, and that nicotine de-
pendence should be measured only by the number of ciga-
rettes smoked per day or the time to the first cigarette of
the day. In addition, defining heavy smoking as more than
30 cigarettes per day would lead to underdiagnosis of indi-
viduals with high nicotine dependence. We therefore
assessed nicotine dependence using the more accurate HSI
and obtained significant results that suggested that low
nicotine dependence was related to the 10r/10r genotype.
Kozlowski et al. [42] suggested that their scales of nicotine
dependence should be limited to predicting how heavily a
person smokes rather than predicting the chances of quit-
ting smoking. Thus, the differing relationships between
smoking cessation and nicotine dependence with genetic
influences are probably not contradictory.
Our finding suggests that variants in CYP2A6 might
affect the association of the VNTR SLC6A3 polymorphism
with nicotine dependence, although no significant associ-
ation was found between the CYP2A6 polymorphism and
nicotine dependence. Because heavy smoking (high HSI
score) was more frequent among individuals carrying the
CYP2A6 *1 allele, these results might indicate an associ-
ation between the CYP2A6 polymorphism and high
nicotine dependence. Kubota et al. [21] had previously
demonstrated that the HSI score was significantly higher
in the CYP2A6 high-activity group carrying the *1 allele
than in the low-activity group (homozygous for minor
alleles, including *4). We found that current smokers
with the 10r/10r genotype were more likely to have low
nicotine dependence based on HSI analysis, although
the genotypic differences between current and former
smokers were not significant for any of the SLC6A3,
ANKK1/DRD2, and CYP2A6 polymorphisms.
Chronic exposure to a low concentration of nicotine is
considered to desensitize nicotinic acetylcholine recep-
tors significantly, which then turn over more slowly [43].
Individuals with high CYP2A6 activity may be able to
maintain a low level of nicotine in the brain, which
might influence dopaminergic activity via the nicotinic
receptor, resulting in a craving for a short term, large
dose of nicotine.
We speculate that the 10r/10r genotype might de-
crease expression of the SLC6A3 protein, which might
result in a chronically high level of extracellular dopa-
mine, protecting them from a craving for heavier smok-
ing. The existence of a null allele in CYP2A6 affects the
related enzyme activity. It is possible that individuals
carrying the *1 allele could inactivate nicotinic receptors
constitutively by the high activity of CYP2A6, decreasing
dopamine release into the synaptic clefts. CYP2A6 poly-
morphisms might mediate the association between the
10r/10r genotype and low nicotine dependence.
Table 3 Profiles of participants were categorized by smoking status for SLC6A3, ANKK1/DRD2, and CYP2A6
polymorphism genotypes
(A) Current smoker
Genotypes Number Age Age at which Duration of
smokingMale Female participant began smoking
SLC6A3 10r/10r 57 4 31.51 ± 11.72 19.33 ± 2.01 11.82 ± 11.12
10r/# or #/# 12 2 36.93 ± 13.36 19.36 ± 1.84 16.43 ± 13.12
P-value 0.119 0.855 0.361
ANKK1/DRD2 A2/A2 25 2 34.05 ± 13.89 19.67 ± 2.15 13.98 ± 13.99
A2/A1 or A1/A1 44 4 31.65 ± 11.09 19.15 ± 1.87 11.95 ± 10.05
P-value 0.435 0.523 0.965
CYP2A6 *1/*1 50 5 32.58 ± 11.79 19.27 ± 2.09 13.05 ± 11.90
*1/*4 or *4/*4 20 1 31.90 ± 13.16 19.14 ± 2.31 11.24 ± 10.73




SLC6A3 10r/10r 15 1 48.69 ± 10.98
10r/# or #/# 4 1 51.2 ± 6.98
P-value 0.901
ANKK1/DRD2 A2/A2 6 0 50.667 ± 8.824
A2/A1 or A1/A1 13 2 48.733 ± 10.760
P-value 0.697
CYP2A6 *1/*1 16 2 49.44 ± 10.56
*1/*4 or *4/*4 3 0 48.33 ± 8.02
P-value 0.840
#DAT alleles with less than 10 repeats. P-value; the Mann–Whitney U test was conducted for participant age and smoking history of each genotype.
Table 5 Effect of genetic polymorphisms and smoking
histories of participants on nicotine dependence in
current smokers: Odds ratios for the SLC6A3, ANKK1/DRD2,
and CYP2A6 genotypes in current smokers with nicotine
dependence
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relationship between nicotine dependence and genetic poly-
morphisms. Our results suggested that the age at which
current smokers began smoking might moderate the effect
of SLC6A3 and CYP2A6 polymorphisms on nicotine de-
pendence. Individuals with the SLC6A3 9r genotypes were
significantly less likely to have started smoking earlier
[10,14]. A previous survey conducted on currently smoking
adolescent subjects demonstrated that individualsTable 4 Odds ratios for the SLC6A3, ANKK1/DRD2, and
CYP2A6 genotypes in current and former smokers
Genotype Number OR (95% CI) P value




10r/# or #/# 14/5, 12/4




A2/A1 or A1/A1 48/15, 44/13




*1/*4 or *4/*4 20/3, 20/3
Each analysis was performed for the whole cohort (the left side) and the male
subgroup only (the right side). #DAT alleles with less than 10 repeats. Number,
current smokers per former smokers; OR, odds ratio; and CI, confidence interval.
Genotype Number OR (95% CI) P value
SLC6A3 10r/10r 9/52, 8/49 0.130 (0.036–0.464),
0.117 (0.030–0.459)
0.002, 0.003
10r/# or #/# 8/6, 7/5
ANKK1/DRD2 A2/A2 4/23, 4/21 0.468 (0.136–1.615),
0.571 (0.161–2.032)
0.352, 0.570
A2/A1 or A1/A1 13/35, 11/33
CYP2A6 *1/*1 15/39, 13/36 3.654 (0.757–17.634),
3.250 (0.661–15.979)
0.165, 0.235
*1/*4 or *4/*4 2/19, 2/18
Each analysis was performed for the whole cohort (the left side) and the male
subgroup only (the right side). #DAT alleles with less than 10 repeats. Number,
numbers of subjects respectively indicated with high (≥ 4) per low scores (< 4)
of HSI, Heavy Smoking Index (summary score of the number of cigarettes smoked
per day and the time to the first cigarette of the day extracted from the Fagerstrom
Test for Nicotine Dependence) in current smokers; OR, odds ratio; CI, confidence
interval.
Table 6 Effect of genetic polymorphisms and smoking
histories of participants on nicotine dependence in
current smokers: Regression analysis of the effect of
combinations of genetic polymorphisms on nicotine
dependence
Genes R2 AIC P-value
SLC6A3 0.054, 0.048 77.940, 72.719 0.025, 0.040
SLC6A3 + ANKK1/DRD2 0.057, 0.260 78.660, 74.262 0.045, 0.098
SLC6A3 + CYP2A6 0.098, 0.087 75.327*, 70.761 0.009, 0.018
Each analysis was performed for the whole cohort (the left side) and the male
subgroup only (the right side). Forward-selection regression began with the
effect of the SLC6A3 polymorphism alone. Variables were added one at a time
to the model until no remaining variable produced a significant result. SLC6A3:
input 1 or 0 for the 10r/10r or other genotype, respectively; ANKK1/DRD2: input
1 for the A2/A2 genotype, 0 for the A1/A2 or A1/A1 genotypes; CYP2A6: input
1 for the *1/*1 genotype, 0 for genotypes including the *4 allele. R2, squared
multiple correlation coefficient adjusted for degrees of freedom; AIC, Akaike’s
information criterion. *The appropriate model was selected on the basis of
minimising AIC.
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intention to quit smoking than their allelic counterparts
[18] did. Our findings suggested that the age of smoking
initiation might be associated with nicotine dependence,
under the influence of the SLC6A3 VNTR polymorphism.
Our results showing an association between the ANKK1/
DRD2 TaqIA polymorphism and smoking status were not
consistent with previous data on Japanese males [6,7]. Pre-
vious studies have suggested that the A2/A2 genotype
increased the risk of being a current smoker among the
Japanese population, whereas studies with Caucasian sub-
jects suggested that the A1 allele was associated with sus-
ceptibility to smoking [4,5]. A previous meta-analysis [44]
suggested a lack of association between the TaqIA poly-
morphism and smoking behaviour and found evidence of
strong heterogeneity between studies. No association of the
HSI score with TaqIA polymorphism was observed in this
study. The TaqIA polymorphism may thus not have a
simple association with smoking status and nicotine
dependence.Table 7 Effect of genetic polymorphisms and smoking
histories of participants on nicotine dependence in
current smokers: Regression analysis of the effect of
smoking history on the association between genetic
polymorphisms and nicotine dependence
Variable R2 AIC P-value
SLC6A3 + CYP2A6 0.098, 0.087 75.327, 70.761 0.009, 0.018
SLC6A3 + CYP2A6 + A 0.133, 0.110 74.250*, 69.921 0.007, 0.014
SLC6A3 + CYP2A6 + D 0.127, 0.101 74.808, 70.615 0.009, 0.019
Each analysis was performed for the whole cohort (the left side) and the male
subgroup only (the right side). Forward-selection regression was conducted with
the effect of the SLC6A3 and CYP2A6 genes. Variables were added one at a time
to the model until no remaining variable produced a significant result. A: age at
which participant began smoking, D; duration of smoking. R2, squared multiple
correlation coefficient adjusted for degrees of freedom; AIC, Akaike’s information
criterion. *The appropriate model was selected on the basis of minimising AIC.The TaqIA polymorphism was originally thought to be
located in the 3′-untranslated region of DRD2, but recent
evidence suggests that it lies within the region encoding
the putative substrate-binding domain of ANKK1 [3]. The
role of ANKK1 has not been fully elucidated, but the
TaqIA polymorphism may be in linkage disequilibrium, in
an ethnic group-specific manner, with unidentified poly-
morphisms in a neighbouring gene that functions in the
signal transduction pathway and that has a stronger influ-
ence on dopamine reward processing.
There are several limitations to this study. First, the
small sample size must be noted. The inconclusive results
may have been the result of insufficient statistical power
to detect associations with small effects. Because of the
small sample size, we did not standardize the environmen-
tal factors in detail, which may have caused selection and
confounding biases. Second, the accuracy of the self-
reported questionnaire was not validated, and the screen-
ing test for nicotine dependence did not type participants
into subtypes. Third, the molecular mechanisms under-
lying the associations between the SLC6A3 VNTR and
ANKK1/DRD2 TaqIA polymorphisms and smoking be-
haviour are uncertain and require clarification.
The degree to which our results can be generalized is
not clear, but the present study provides a preliminary re-
port in a Japanese population, and suggests that genetic
studies on smoking should be based on ethnicity. Future
large analyses on the multiple influences of polymorph-
ism–polymorphism interactions, i.e. among the func-
tional genetic polymorphisms of SLC6A3, ANKK1/
DRD2, CYP2A6, and other related molecules, on smoking
behaviour and nicotine dependence in different ethnic
groups could address the problem of small sample size
and lead to conclusions that are more reliable.Conclusions
The genotyping results suggest that nicotine dependence
in current smokers who are homozygous for the SLC6A3
10r allele was lower than that in individuals carrying the
minor alleles, and that CYP2A6 polymorphisms might
mediate this association. Furthermore, the age at which
smokers begin smoking might moderate the association
between their genetic polymorphisms and nicotine de-
pendence. This study provides preliminary results re-
garding the effect of the SLC6A3 VNTR, ANKK1/DRD2
TaqIA, and CYP2A6*4 polymorphisms on smoking cessa-
tion and nicotine dependence in a Japanese population.Methods
Participants
Ninety-six Japanese ever-smokers were recruited from
among the students, staff, and their siblings at Hokuriku
University. The institutional review committee of Hokuriku
Ohmoto et al. BMC Genetics  (2014) 15:151 Page 8 of 9University approved this study, and all participants gave
their informed consent.
Participants were categorized as current smokers
(n = 75, 69 males, 6 females, mean age: 32.52 ± 12.13 years)
or former smokers (n = 21, 19 males, 2 females, mean age:
49.29 ± 10.07 years) if they had quit at least 1 year prior to
the interview. The current smokers completed the FTND
[40] as a self-reported measure of nicotine dependence
and a lifetime history of cigarette smoking (the age at
which they began smoking and the number of years they
had smoked) was collected. Nicotine dependence was esti-
mated by the HSI, which is based on two items extracted
from the FTND: the number of cigarettes smoked per day
and the time to the first cigarette of the day. A cut-off
score of HSI ≥ 4 was used to categorize individuals as
highly dependent on nicotine [41].
Genotyping
Buccal swabs were collected from all participants and DNA
was extracted with a DNA extraction kit (EPICENTRE®
Biotechnologies, Madison, WI). The SLC6A3 VNTR poly-
morphisms were amplified by PCR [33] and resolved on
1.5% agarose gels using positive controls obtained by direct
DNA sequencing. To genotype the TaqIA polymorphism,
the amplicons were digested with TaqI [4] and resolved on
2% agarose gels. The genotyping of CYP2A6*4 was per-
formed by the PCR-RFLP method, using digestion with
Eco81I [45].
Statistical analyses
The genotypes of the polymorphisms were classified by
the homozygosity of the major alleles as follows. SLC6A3
VNTR: 10r/10r versus 10r/* or */*, where * refers to alleles
with fewer than 10 repeats; TaqIA: A2/A2 versus A1/A2
or A1/A1; CYP2A6*4: *1/*1 versus *1/*4 or *4/*4. The
VNTR,TaqIA, and CYP2A6*4 polymorphisms were tested
for HWE in current smokers, former smokers, and the
whole cohort.
The effect of the genetic polymorphisms on smoking
cessation and the genotype frequency among the current
and former smokers, and nicotine dependence estimated
by the HSI score among current smokers, were examined.
These analyses were conducted for both the whole cohort
and male subjects only, because female participants
accounted for only 8.3% of the cohort. Chi-squared ana-
lyses with the Yates correction were conducted to examine
the association of genotype with smoking status and nico-
tine dependence. P < 0.01 and a 95% confidence interval
(CI) that did not include a value of 1.0 were considered
statistically significant. The associations were further
expressed as odds ratios (OR) with a 95% CI.
We investigated the degree of nicotine dependence
(the HSI score) among the current smokers generated
by polymorphism–polymorphism interactions and thesmoking histories of participants by two approaches using
regression analysis. First, regression analyses were per-
formed based on a method of forward-stepwise selection,
by fixing the genetic polymorphism determined to be sta-
tistically significant by chi-squared analyses. Second, we
performed forward-stepwise analyses using the two-
variable combination of the age at which smoking began
and the duration of smoking to determine the effect of
smoking history on the relationship between nicotine de-
pendence and the genetic polymorphism. The most
appropriate model was selected based on Akaike’s in-
formation criterion (AIC). P < 0.01 was used as the cut-off
for statistical significance.
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